Treating the Primary in High vs Low Volume Hormone Sensitive Disease - Interview Noel Clarke
Noel Clarke
Using various volume and risk criteria used worldwide for the treatment related to docetaxel and abiraterone in metastatic hormone-sensitive prostate cancer, Noel Clarke and colleagues have gathered and correlated large volumes of imaging data on treatment and outcomes from within the UK within the STAMPEDE trial.